Monotherapy of an NMDA Enhancer for Schizophrenia

Last updated: March 21, 2026
Sponsor: China Medical University Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Tourette's Syndrome

Psychosis

Schizotypal Personality Disorder (Spd)

Treatment

Placebo Cap

NMDAE

Clinical Study ID

NCT04745143
CMUH105-REC1-050
  • Ages 18-65
  • All Genders

Study Summary

Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia

  • Refuse or are unable to tolerate antipsychotics due to poor response or adverseeffects

  • PANSS total score ≥ 60

  • Free of antipsychotic drugs for at least 1 week

  • Agree to participate in the study and provide informed consent

Exclusion

Exclusion Criteria:

  • Current substance abuse or history of substance dependence in the past 3 months

  • History of epilepsy, head trauma, stroke or other serious medical or neurologicalillness which may interfere with the study

  • Use of depot antipsychotic in the past 3 months;

  • Clinically significant laboratory screening tests

  • Pregnancy or lactation

  • Inability to follow protocol

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Placebo Cap
Phase: 2
Study Start date:
January 01, 2018
Estimated Completion Date:
December 31, 2027

Study Description

Several lines of evidence suggest that schizophrenia is associated with accelerated aging and oxidative stress may play a role. Cognitive deficits are core symptoms of accelerated aging in patients with schizophrenia and the most difficult domain to treat. Current antipsychotics have limited, if any, efficacy for cognitive function. Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing not only clinical symptoms but also cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. This study aims to examine the efficacy and safety of NMDAE monotherapy for the treatment of schizophrenia. The investigators enroll patients with schizophrenia who refuse or are unable to tolerate antipsychotics due to poor response or adverse effects into a 6-week randomized, double-blind trial to receive monotherapy of NMDAE or placebo. The investigators biweekly measure clinical performances and side effects. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of NMDAE and placebo will be compared.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

Connect with a study center

  • Department of Psychiatry, China Medical University Hospital

    Taichung,
    Taiwan

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.